BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Deals

  Panbela Announces Closing of Approximately $9.0 Million Public Offering

  Panbela Therapeutics, Inc. today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock.

  February 1, 2024

   · 

  5 min read
• Business

  Labcorp Named One of the World’s Most Admired Companies™ by FORTUNE® Magazine

  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine’s list of the World’s Most Admired Companies™, a recognition of the most respected and reputable companies globally.

  February 1, 2024

   · 

  1 min read
• Business

  Remix Therapeutics Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer

  Remix Therapeutics today announced the appointment of Dominic Reynolds, Ph.D., as Chief Scientific Officer (CSO).

  February 1, 2024

   · 

  2 min read
• Deals

  Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.

  Numinus Wellness Inc. announces today that it has entered into an agreement to divest its holdings in Alto Neuroscience Inc. (“Alto”), a clinical-stage biopharmaceutical company.

  February 1, 2024

   · 

  3 min read
• Business

  Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

  Takeda announced financial results for the third quarter of fiscal year 2023. With year-to-date strong momentum in its Growth & Launch Products offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year Management Guidance.

  February 1, 2024

   · 

  11 min read
• Drug Development

  Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation

  Sensorion announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.

  February 1, 2024

   · 

  5 min read
• Business

  Legacy Novozymes delivers solid last full-year results

  In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.

  February 1, 2024

   · 

  2 min read
• Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

  To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization, has expanded its DMPK capabilities.

  February 1, 2024

   · 

  3 min read
• Policy

  Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

  Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.

  February 1, 2024

   · 

  2 min read
• LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

  LimmaTech Biologics announced a second closing of its Series A financing, raising an additional USD 3 million from new investor Tenmile, bringing the total raised to USD 40 million.

  February 1, 2024

   · 

  3 min read